News – Page 97 – Endpoints News

Exclusive: A small San Diego biotech wants to change how Parkinson’s disease is diagnosed

8 months ago

Pfizer's former top executives pitched changes to board as part of activist's plan

8 months ago

Black Diamond cuts workforce, prioritizes lung cancer drug

8 months ago

Scholar Rock aims to raise $275M; Vincerx to reshuffle pipeline focus

8 months ago

Biogen to seek approval for high-dose Spinraza after unveiling new data

8 months ago

Orasis snags $78M to launch presbyopia eye drops more than a year after FDA approval

8 months ago

Exclusive: Lilly backs a16z-funded Arda Therapeutics' $43M Series A to take ADCs into fibrosis

8 months ago

Sage faces third study fail in six months as Alzheimer's candidate misses Phase 2 goal

8 months ago

Astellas places new bet on gene therapy in $50M upfront deal with UK startup

8 months ago

Merck partners with small UK biotech to drug fibroblasts for fibrosis, I&I diseases

8 months ago

Exclusive: Tiny startup with big vision to extend healthspan by 20 years says it discovered an ‘Atlas of ...

8 months ago

J&J’s ‘pretzel’ drug-device therapy fails in certain bladder cancer patients

8 months ago

Novo and Viatris settle Ozempic patent suit as generic entry date remains unknown

8 months ago

Many drug price proposals from candidates and Congress won't have much effect, analysis finds

8 months ago

Supreme Court declines to review patent battle over inhalation powder Yutrepia

8 months ago

Post-Hoc: What does an activist want with Pfizer?

8 months ago

Scholar Rock claims success in Phase 3 spinal muscular atrophy study, stock soars

8 months ago

AstraZeneca makes another cardio deal, betting $100M on China company’s lipid drug

8 months ago

Special report 2024: Meet 20 women breaking new ground in biopharma R&D

8 months ago

Galapagos investor gets board seat; OnKure completes merger with Reneo

8 months ago

Oaktree creates third life sciences SPAC, following success with Hims & Hers and Alvotech

8 months ago

Judo Bio launches with $100M for kidney-targeted siRNA therapies

8 months ago

Upstream and CAMP4 target $182M, $67M IPOs

8 months ago

FDA puts Kezar lupus trial on hold after earlier report of patient deaths

8 months ago

First page Previous page 94 95 969798 99 100 Next page Last page